--- title: "Weekly Recap | CVS Health +7.2%, most brokers rate it buy" type: "News" locale: "en" url: "https://longbridge.com/en/news/302170141.md" description: "CVS Health rose 7.2% to close at $92.36 this week, outperforming the S&P 500 by roughly 9.15 percentage points as the benchmark fell 1.95%. The move higher was front-loaded but not a straight line: Monday opened low and finished at $87.74, Tuesday slipped to $87.55, then Wednesday, Thursday and Friday pushed steadily higher, with Thursday closing at $92.58 and Friday ending at $92.36 after trading between $93.03 and $92.05. Weekly amplitude was 8." datetime: "2026-10-17T06:56:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/302170141.md) - [en](https://longbridge.com/en/news/302170141.md) - [zh-HK](https://longbridge.com/zh-HK/news/302170141.md) generator: "portal-rs" --- # Weekly Recap | CVS Health +7.2%, most brokers rate it buy ## The Week CVS Health rose 7.2% to close at $92.36 this week, outperforming the S&P 500 by roughly 9.15 percentage points as the benchmark fell 1.95%. The move higher was front-loaded but not a straight line: Monday opened low and finished at $87.74, Tuesday slipped to $87.55, then Wednesday, Thursday and Friday pushed steadily higher, with Thursday closing at $92.58 and Friday ending at $92.36 after trading between $93.03 and $92.05. Weekly amplitude was 8.43%, with the stock advancing against a drawdown in the broader market. ## Key Events The week’s central story was the opioid prescription case settlement. On 14 October, CVS reached a deal with the US Justice Department over alleged illegal opioid prescriptions, agreeing to pay $315 million. The same day brought news that NorthCrest Asset Management had boosted its stake, alongside reports examining whether CVS insiders breached fiduciary duties to shareholders. Early in the week, Leerink Partners maintained its outperform rating with a $112 price target. On 15 October, CVS announced a partnership with The Midlife Collective to study women’s midlife health. Overall, the news flow was dominated by the settlement and analyst commentary, while the stock ran ahead of the market through the week. ## Analyst Ratings Among the 27 institutions covering CVS, 18 rate it buy, 7 rate it overweight, and 2 rate it hold, with no underweight or sell ratings. The consensus recommendation is strong buy, and the consensus target price is $115.48, about 25.03% above the current level. Target prices range from $103 to $145, a fairly wide spread. Within the healthcare services industry, CVS ranks 1st out of 53 by number of broker ratings, versus an industry mean of 9 and median of 7. ## The Week Ahead US macro data is dense in the coming week: the NAHB housing market index on 19 October, housing starts and building permits on 20 October, and EIA crude oil and Cushing inventory figures on 21 October. On the company side, CVS reports fiscal third-quarter 2026 results on 4 November before the market opens, with consensus estimates at $1.2921 for EPS and $104.8bn for revenue. That results date is the key single-stock calendar item after this week. ## In Short The tension this week is between price action and positioning. CVS rallied against a falling market, and the opioid settlement removed one regulatory overhang. Broker coverage is the broadest in its industry, with a strong-buy consensus and a target above spot by around 25%, while valuations sit at about 24.16x P/E and 1.48x price-to-book. The latest daily fund flow snapshot shows large-lot money turning net buyer, though small and medium flows were net sellers, leaving mixed signals. The next test is the third-quarter earnings release on 4 November, and whether macro data shifts risk appetite for healthcare names. *This article is generated by LongbridgeAI from market data, for information only and not investment advice.* ### Related Stocks - [CVS.US](https://longbridge.com/en/quote/CVS.US.md) ## Related News & Research - [CVS Agrees to $315 Million Settlement Over Alleged Illegal Opioid Prescriptions](https://longbridge.com/en/news/301843746.md) - [CVS Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CVS Health Corporation - CVS](https://longbridge.com/en/news/301447898.md) - [GRAPHIC-Take Five: AI trade meets the Fed](https://longbridge.com/en/news/302836715.md) - [IREN Stock: Why Analysts Still See Over 200% Upside Despite This Week's Plunge](https://longbridge.com/en/news/302922686.md) - [Oracle Stocks Edge Up as $1 Billion Backs AI Partners](https://longbridge.com/en/news/302919901.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**